In the UK, chloral hydrate is prescribed for severe insomnia after behavioural/drug therapies fail. It is not routine long-term therapy. UK leaflet.
- Have a written reason, review contact and stopping plan before leaving the prescribing appointment.
- Restricted pediatric insomnia and supervised procedural sedation have separate pathways. MHRA.
- Dependence and withdrawal need review; do not increase the medicine yourself.
- Suspected overdose needs immediate medical help. Do not wait to see whether the person wakes normally. NHS.
- The manufacturer-funded RESTORE study cannot establish independent benefit or comparative safety.
Table of contents
- Evidence summary
- What chloral hydrate is: liquids, Welldorm and cloral betaine
- How it works: the active metabolite and sedation
- Insomnia and procedural sedation
- Supplement and lifestyle evidence: no substitute regimen
- What works and what remains unestablished: the RESTORE trial
- Overdose, allergy and impaired alertness
- Alcohol and drug interactions
- Contraindications
- Clinician-led use: liquid strength, missed doses and review
- Animal and human uncertainty
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| UK insomnia scope | Selected severe insomnia, maximum two weeks | Maker labels; fee-connected regulator | A prescribing boundary, not independent efficacy. |
| RESTORE | Adult, single-arm short course | Pharmanovia; paid company/CRO relationships | Excluded from independent efficacy; no control or long-term certainty. |
| Procedural sedation | CUH CT/MRI instructions | Provider revenue; contributor chains unclosed | Supervised local care, not home insomnia instructions. |
| Breastfeeding | LactMed versus UK leaflet | Publisher/author and old-study gaps | Qualified assessment differs from label; no blanket safety claim. |
| Supplements | NCCIH safety and uncertainty | Dated public routes; reviewer/trial gaps | No independent substitute or combined regimen established. |
What chloral hydrate is: liquids, Welldorm and cloral betaine
Welldorm Elixir contains 143.3 mg of chloral hydrate per 5 ml. This identifies concentration, not your dose. Product identity.
Another UK liquid contains 500 mg per 5 ml. 500-strength label.
Welldorm tablets contain cloral betaine, a distinct prodrug that releases chloral hydrate. Its historical label had an age threshold of 12 years; the current eMC entry is marked discontinued. Do not substitute a tablet for a liquid or assume that a past brand licence means it is available now. Historical tablet label.
Equal volumes of different strengths are not equivalent.
How it works: the active metabolite and sedation
Chloral hydrate becomes active sedative trichloroethanol; the label discusses proposed inhibitory GABA signalling. Professional pharmacology.
Our review does not infer from sedation that a medicine repairs insomnia’s cause, restores normal sleep architecture or prevents long-term illness.
The practical treatment question is whether a defined, supervised course helps the problem for which it was prescribed with acceptable harms. Feeling knocked out is not an adequate treatment goal by itself. Keep the agreed goals specific enough for a review: the sleep complaint, daytime impairment and unwanted effects matter together.
Insomnia and procedural sedation
The October 2021 restriction limits courses to two weeks. From age two, pediatric insomnia use requires suspected/definite neurodevelopmental disorder, severe daily-life impairment and failed behavioural/drug therapies, alongside behavioural care. Repeated courses need specialist reassessment. MHRA.
The label says children’s use is generally not recommended and requires specialist supervision. Pediatric label.
Insomnia assessment considers causes such as pain, anxiety, medicines, shift work, sleep apnea or restless legs. NHS care includes treating the underlying problem and cognitive behavioural therapy, delivered in person or online. A sedative prescription does not remove the need for that assessment. Insomnia care.
CUH describes chloral hydrate during supervised CT sedation, with staff-led assessment, monitoring and recovery. Procedure instructions—including route, preparation and discharge decisions—are separate from insomnia prescribing. A child who has recently been ill needs the procedure team’s advice; do not improvise preparation or administer someone else’s sedative. CT service leaflet.
CUH’s MRI sedation pathway also uses written preparation and staff supervision. Take the procedure team’s instructions to the appointment and tell them about other medicines and new illness. This article does not copy fasting, sleep-deprivation or discharge schedules; different services and procedures require their own plan. MRI service leaflet.
Before a sleep prescription, ask what diagnosis or short-term problem it is addressing and what failed treatments actually involved. Before a procedure, ask the unit who supplies and administers the medicine and whom to contact if preparation cannot be followed. Those are different conversations, even when the ingredient is the same.
Supplement and lifestyle evidence: no substitute regimen
NCCIH describes uncertain valerian evidence and serious liver-injury concerns with kava. This review does not establish an independent supplement replacement for chloral hydrate or a combination that improves its safety. “Natural” and prescription products should not be layered into an unsupervised sleep regimen. Complementary approach limits.
Give the prescriber or pharmacist the actual ingredient lists for supplements and non-prescription sleep products. NCCIH notes that supplements can interact with medicines and may differ from their advertising. A label’s marketing language cannot establish compatibility with a prescribed sedative. Supplement safety.
NHS insomnia advice includes a regular sleep routine, a suitable bedroom and addressing habits that disrupt sleep. These measures support care; persistent impairment still needs assessment. Do not drive when sleepy, whether the sleep problem, the medicine or both may be responsible. Sleep routine.
Bring a record of what you already tried rather than a list of products you intend to add. Ask which parts of the behavioural plan remain appropriate during the prescribed course. This helps the review distinguish the medicine’s intended role from a changing mixture of sleep products and routines.
What works and what remains unestablished: the RESTORE trial
RESTORE enrolled 96 adults in a remote, single-arm open-label study with a two-week course and short follow-up. It reported improvements, but lacked a placebo or active comparator; self-report, concurrent behavioural care and missing diary data complicate interpretation. Pharmanovia funded it; company/CRO employees and paid consultants were involved. Its results are excluded from this article’s independent efficacy verdict. Actual 2026 study.
The HRA application separately identifies Pharmanovia, legally Atnahs Pharma UK, as sponsor. Ethics approval and hosting on a public regulator’s website do not turn a sponsor’s application into independently funded research or prove benefit. Sponsor record.
No independent superiority ranking or long-term benefit claim is established by the sources reviewed here. This means the relevant question remains unresolved under the stated funding screen; it does not mean every patient will fail to benefit. A product’s licensed role, a clinician’s individual decision and an independently established comparative outcome are different claims.
Overdose, allergy and impaired alertness
Suspected extra intake requires immediate emergency-department or doctor contact. Bring the container. Do not wait for symptoms or attempt another dose or home reversal. Leaflet overdose action.
NHS poisoning advice says to call 999 or attend emergency care for suspected harmful exposure; unconsciousness, stopped or severely difficult breathing or a seizure are emergencies. Outside the UK, use your local emergency service. Do not drive yourself, induce vomiting or give food or drink while awaiting help. Current poisoning advice.
Swelling of the lips, tongue, mouth or throat, trouble breathing or swallowing, or collapse can signal anaphylaxis: get emergency help immediately. Do not treat this as ordinary sleepiness or wait for the next appointment. Serious allergy action.
Tolerance, dependence, misuse and withdrawal occur. Abrupt stopping after prolonged use can cause delirium/hallucinations; withdrawal needs supervision. Frail older people are vulnerable to confusion, poor coordination and falls. Prior alcohol/drug dependence warrants assessment for misuse risk. Report reduced effect rather than increasing intake. Dependence precautions.
Stop and get urgent medical advice for slow/shallow breathing or abnormal heartbeat; do not drive or operate machinery while impaired. Leaflet safety.
Other listed effects include headache, anxiety/excitation, ataxia and gut upset. Reported effects.
A fall deserves assessment of injury, mobility and possible medicine contribution. NHS advice includes reviewing medicines and reducing household hazards; inability to get up or suspected significant injury needs urgent help. Do not dismiss a new fall as an unavoidable price of getting sleep. Falls assessment.
Alcohol and drug interactions
Alcohol and concurrent CNS depressants should be avoided: opioids, benzodiazepines, sedating antihistamines, antipsychotics, antidepressants, antiepileptics, anaesthetics and muscle relaxants. QT-prolonging or potassium/magnesium-lowering medicines increase rhythm risk. The label flags intravenous furosemide, anticoagulant monitoring with chloral changes, and thyroid-test interference. No formal pharmacokinetic interaction studies. Interactions.
Review all medicines and supplements with a pharmacist; do not stop essential treatment or assume unlisted combinations safe.
Contraindications
Contraindications include severe liver/kidney/heart disease, active gastritis/esophagitis, gastric/duodenal ulceration/perforation, acute porphyria susceptibility, ingredient allergy and rare glucose-galactose malabsorption. Contraindications.
The UK leaflet prohibits use while pregnant, breastfeeding or trying to conceive. Contact the treating team about exposure or planned pregnancy; do not choose a replacement yourself. Reproductive restriction.
LactMed’s September 2024 assessment is more qualified than the UK leaflet: it discusses occasional or short-term exposure, but favours alternatives for prolonged use, particularly with a newborn or preterm infant. Evidence includes very old and partly mixed-drug observations. That discussion is not proof of infant safety or permission to override the UK label; obtain individual prescribing and infant assessment. LactMed limits.
Ask the specialist which pathway applies; never copy an adult prescription or procedural plan for home childhood insomnia.
Clinician-led use: liquid strength, missed doses and review
Use the exact product’s supplied syringe/adapter and instructions. The 500 mg/5 ml leaflet says to omit a missed dose, then take the next at the usual time; never double. Store away from children. Product handling.
This guide intentionally gives no starting amount, escalation, liquid conversion, repeat-course schedule or taper. Confirm the exact prescription with the pharmacist, especially if a bottle or measuring device changes. Ask what to do if the instructions are unclear, medicine is spilled, an extra amount is taken or the planned review cannot happen. A new bottle should not silently become a new treatment plan.
At the review, ask whether the original goal was met, what unwanted effects need follow-up and what happens next. Bring the bottle and medicine list. Describe the actual use history honestly, including any departure from the written plan. Ask who coordinates the next step and how you contact them if the plan is unclear.
Animal and human uncertainty
The MHRA cites animal carcinogenicity and missing long-term studies: prolonged-use human risk cannot be excluded. This neither proves short-course cancer harm nor establishes chronic safety. Regulatory uncertainty.
Laboratory signals and regulatory precaution answer different questions from a controlled human outcome study. This guide therefore uses the warning to explain the limit of available long-term knowledge, without translating animal exposures into a personal risk estimate or claiming that a short-term clinical observation resolves the uncertainty.
Funding and source roles
Research funding at a glance
43 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS national website content policy | Dated DHSC website funding; no ads/corporate sponsorship stated. Individual provider finances and current contracts unclosed. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional process self-report. Reviewed 14 October 2022; October 2025 review due has passed. |
| NCCIH FY 2025 congressional justification | NIH/HHS federal budget route; historical request, not current enactment. Gifts/page allocation unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional historical self-report. Page says it no longer reflects current HHS policy; budget-advocacy incentives. |
| NCCIH: sleep and complementary approaches | Dated fiscal route below. Credited NCCIH reviewers’ outside interests and original-study finances unclosed. | United States; Bethesda, Maryland | Tier 2 — public safety/uncertainty context | C provisional. May 2024. Public education; no independent product efficacy adopted. |
| NCCIH: supplement safety | See dated fiscal row; page/expert and original-study finance unclosed. | United States; Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Footer January 2019 despite later references; date limit retained. |
| MHRA: 2025/26 audited accounts | Industry statutory fees and nonstatutory customer charges, plus DHSC grant-in-aid. Licence/vigilance fees document an industry relationship; warning/adviser allocation unknown. | UK; 10 South Colonnade, London | Tier 3 — institutional financial self-report | B provisional financial facts. Published 15 July 2026; selected audited notes, not full backer clearance. |
| eMC: publishing and payment process | Datapharm owns/manages eMC; pharma subscriptions pay for publishing. Companies draft/publish regulator-approved labels; complete ultimate-owner chain unclosed. | UK; Cassini Court, Randalls Way, Leatherhead | Tier 4 — paid maker publishing channel | B provisional process facts; D for independent efficacy. Paid-publication incentives persist after regulatory review. |
| NHSBSA: chloral hydrate item count | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: item-count methods | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 3 — institutional method self-report | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: 2025/26 publication | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: 2025/26 audited institutional accounts | DHSC sponsor/appointed board; main Parliamentary support plus full-cost service-contract income and public repayment work. Separate student-support routes. Specific PCA allocation and staff/contractor interests unknown. | United Kingdom; Stella House, Goldcrest Way, Newcastle upon Tyne | Tier 3 — institutional financial/identity self-report | B provisional. Report printed 13 July 2026. Accountability/service incentives; selected notes read, complete subsidiary/backer audit unclosed. |
| NHS: falls and medicine review | Dated national policy below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 6 March 2025. Public-service incentives; no cleared drug outcome. |
| Chloral hydrate 500 mg/5 ml: SmPC | Marlborough; backers below. Paid eMC; receipts unclosed. | UK licence; Basildon | Tier 4 — maker-produced or sponsored; self-interest | D. Text 17 August 2026; posted 24 August. Safety context. |
| Chloral hydrate 143 mg/5 ml: SmPC | Marlborough holder; group/backer rows below. Product revenue and supporting trials unclosed. | UK licence; Basildon, England | Tier 4 — maker-produced or sponsored; self-interest | D for independent efficacy. Text 31 October 2025; posted 24 November. Product-specific safety context. |
| Chloral hydrate 500 mg/5 ml: leaflet | Marlborough; Waymade UK/Laboratorium Sanitatis Spain manufacturers. Backers below; batch unclosed. | UK licence; UK/Spain manufacturing | Tier 4 — maker-produced or sponsored; self-interest | D for independent efficacy. August 2023 text; posted 30 July 2026. Not later SmPC revision. |
| Chloral hydrate 143 mg/5 ml: leaflet | Marlborough; listed UK/Spain manufacturers. Generic factories/payments unclosed. | UK licence; UK/Spain manufacturing | Tier 4 — maker-produced or sponsored; self-interest | D. April 2022 text; posted 18 May 2022. Dated restrictions. |
| Welldorm Elixir: professional label | Marlborough product; backers below. Same maker family, no independent corroboration. | UK licence; Basildon, England | Tier 4 — maker-produced or sponsored; self-interest | D for independent efficacy. Text 31 October 2025; posted 24 November. Brand, metabolism and handling context. |
| Welldorm cloral betaine tablets: historical label | Marlborough commercial product; group below. Current eMC entry says discontinued; stock/alternative suppliers unclosed. | UK historical licence; Basildon, England | Tier 4 — maker-produced or sponsored; self-interest | D for independent efficacy. July 2021 text, December 2021 posting. Historical product identity, not current availability. |
| MHRA: chloral pediatric restriction | Industry-fee/public agency route below. Warning allocation and advisers’ outside interests unclosed. | UK regulator; London | Tier 3 — industry-fee regulator; safety context | C provisional. 6 October 2021. Statutory safety role; underlying efficacy/trial finance not cleared. |
| RESTORE: 2026 insomnia study | Pharmanovia funded; Lindus Health ran study; paid Salve writing. Sponsor/CRO employees; Williams/Groeger paid Lindus consultants. | UK study/companies | Tier 4 — maker-produced or sponsored; self-interest | D for independent efficacy. 19 May 2026; single-arm/open-label, self-report and missing data. Commercial results excluded from verdict. |
| HRA-hosted RESTORE application | Record names Pharmanovia (Atnahs Pharma UK) as sponsor. Public hosting does not make applicant content independent. | England; sponsor/host London/Basildon | Tier 4 — maker-produced or sponsored; self-interest | D for independent efficacy. REC decision 21 August 2023; NCT06053840. Applicant self-report, not outcome validation. |
| HRA: 2025/26 financial statements | DHSC grant-in-aid; devolved-administration service fees and other NHS/non-NHS revenue. No RESTORE allocation inferred. | UK; host, 2 Redman Place, London | Tier 3 — institutional financial/process self-report | B provisional. Updated 9 July 2026. Selected statements/notes read, not full receipt audit. Distinct from MHRA fees. |
| NHS: insomnia care | Dated national policy row; page/contributor/trial finance unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 19 March 2024; due March 2027. Care education, not cleared comparative efficacy. |
| NHS: poisoning emergency advice | National policy below; exact page and adviser allocation unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 12 June 2025. Public urgent-care instructions; not a chloral toxicity estimate. |
| NHS: anaphylaxis | National policy below; exact contributor and page finance unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 21 June 2023; June 2026 deadline passed. Clear emergency-action context. |
| CUH: CT under oral sedation | Provider’s own accounts below; exact leaflet allocation and contributor outside interests unclosed. | UK; Cambridge University Hospitals, Cambridge | Tier 2 — public clinical context; provisional | C provisional. 30 October 2025, version 6. Local clinical instructions; no procedure outcome comparison. |
| CUH: MRI under oral sedation | Provider’s own accounts below; exact leaflet allocation and contributor outside interests unclosed. | UK; Cambridge University Hospitals, Cambridge | Tier 2 — public clinical context; provisional | C provisional. 10 November 2025, version 5. Local clinical instructions; no procedure outcome comparison. |
| CUH: FY2025–26 audited accounts | NHS commissioning, private/overseas care, research/training, capital donations and other income; industry/academic partnerships. No leaflet allocation inferred. | United Kingdom; NHS Foundation Trust, Cambridge | Tier 3 — financial self-report/statutory accounts | B provisional. Income notes 2.1–2.3 and partnership text read; care, commercial and budget incentives. |
| LactMed: chloral hydrate | NICHD publisher routes below; Anderson process/declaration separate. Chapter allocation and old primary-study finances unclosed. | US; publisher Bethesda, Maryland | Tier 2 — public clinical context; provisional | C provisional. 15 September 2024. Very old, partly mixed-drug observations; not proven infant safety or UK label override. |
| LactMed: creation/review process | Primary compiler Philip O. Anderson, UC San Diego; NLM editorial support and named reviewer panel. Current chapter reviewer/fee allocation unknown. | US; UC San Diego/NLM; Canadian reviewer | Tier 3 — institutional financial/process self-report | B provisional process self-report. Undated chapter; peer review is not financial clearance. |
| Anderson coauthored study: 2025 declaration | SickKids Sellers endowed chair and CIHR fellowship BPF-192544; authors declare no competing interests for this work. Endowment donor chain unclosed. | Canada/US; Toronto, Halifax, UC San Diego | Tier 3 — institutional financial/process self-report | B provisional dated self-declaration. First published 13 August 2025; January 2026 issue. Not his 2024 LactMed contract audit. |
| NICHD: budget route | Congressional budget/justification route; page does not close current enacted appropriation or LactMed allocation. | US; federal NICHD, Bethesda | Tier 3 — institutional financial/process self-report | B provisional. Last reviewed 2 June 2025. Budget advocacy/self-report; amounts not adopted as current funding. |
| NICHD: gifts and partnerships | Statutory gift/bequest authority and partnership route; no present gift amount, named payer or LactMed allocation proven. | US; federal NICHD, Bethesda | Tier 3 — institutional financial/process self-report | B provisional dated process self-report. Reviewed 30 December 2017. Authority is not a receipt ledger. |
| Marlborough: legal company record | Company-filed identity; active private medicine manufacturer/wholesaler. No complete product revenue or receipt audit. | UK; Basildon registered office | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Latest accounts period March 2025; 2026 filing not yet due. Registry warns filings not verified. |
| Marlborough control | Company-filed active controller: Atnahs Pharma UK; at least 75% shares/votes and director-appointment rights. Not an exact 100% stake. | UK registered entities | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Current public filing read; no audited beneficial-owner or lender ledger. |
| Atnahs Pharma UK control | Company-filed active controller: Pharmanovia Bidco; at least 75% shares/votes and director-appointment rights. Not an exact 100% stake. | UK registered entities | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Current public filing read; no audited beneficial-owner or lender ledger. |
| Pharmanovia Bidco control | Company-filed active controller: Pharmanovia Midco; at least 75% shares/votes and director-appointment rights. Not an exact 100% stake. | UK registered entities | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Current public filing read; no audited beneficial-owner or lender ledger. |
| Pharmanovia Midco control | Company-filed active controller: Pharmanovia Holdco; at least 75% shares/votes and director-appointment rights. Not an exact 100% stake. | UK registered entities | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Current public filing read; no audited beneficial-owner or lender ledger. |
| Pharmanovia Holdco: control statement | No active registrable PSC; company statement knows no registrable person/relevant legal entity. This does not mean ownerless or investor-free. | UK registered company | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Statement notified August 2019; former named controller ceased. Ultimate interests unclosed. |
| Pharmanovia: group identity | Commercial medicine group: founded as Atnahs, rebranded 2021; original names Triton investment in 2019. Group/backer records separate. | UK; Basildon headquarters | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Own current history/bio; not audited present stake or product profits. |
| Pharmanovia: FY2025 tax strategy | Medicine sale/marketing/distribution; acquisitions financed with external debt. Appendix includes Marlborough and control entities; lenders/amounts unclosed. | UK group; worldwide commercial operations | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Approved 7 April 2025. Own tax/business statement, not complete audited finance. |
| Triton: current Pharmanovia portfolio | Investor lists Pharmanovia as current UK healthcare investment. Exact stake, fund investors and personal receipts unclosed. | UK portfolio; multijurisdiction investor | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Current investor self-report; growth/exit incentive. No ultimate-owner clearance. |
| Triton: legal office identities | Own directory identifies UK adviser, Luxembourg management and Jersey management entities. Fund/beneficial-owner receipts not traced completely. | UK, Luxembourg and Jersey offices | Tier 4 — maker-produced or sponsored; self-interest | D for independent claims. Own contacts; no single worldwide headquarters inferred. |
| Companies House: 2025/26 accounts | Statutory service fees, DBT/Treasury funding and Economic Crime Levy. Host funding is not pharmaceutical company capital. | UK; Cardiff office, UK register | Tier 3 — institutional financial/process self-report | B provisional. Updated 16 July 2026. Selected finance/office passages read; filings remain company-supplied. |
Frequently asked questions
Is cloral betaine the same as chloral hydrate liquid? No. It is a separate prodrug/tablet formulation; do not substitute or convert it yourself. Source.
Can I increase it or stop suddenly? No self-adjustment. Tolerance and withdrawal need review; prolonged use requires supervised stopping. Source.
What should I do after an extra dose? Get immediate emergency or doctor advice, before symptoms; bring the container. Source.
Does a LactMed entry make it safe while breastfeeding? No. Its qualified assessment and old evidence do not override the UK leaflet; maternal and infant circumstances need individual review. Source.
Does RESTORE prove independent benefit? No. Manufacturer funding and an uncontrolled design prevent that conclusion under this article’s evidence screen. Source.
What should I bring to the review? Bring the exact dispensed product, instructions and complete medicine list, plus questions about the original goal, effects and next plan. This is a consultation prompt, not a new prescription.
Sources and funding notes
Reviewed 4 October 2026. Source roles, dates, named relationships and unresolved allocations are stated individually. Approval, public hosting and peer review are not financial clearance. Institutional receipts, personal contracts and trial sponsorship are different questions. No personal regimen or independent sponsored efficacy is adopted. Complete beneficial-owner and payment chains remain unresolved.
- NHS national website content policy — National website policy, not provider or trial finance.
- NCCIH FY 2025 congressional justification — Institutional route only; no present appropriation or product efficacy.
- NCCIH: sleep and complementary approaches — Valerian uncertainty, kava hazard and no substitute claim.
- NCCIH: supplement safety — Full ingredient disclosure and interaction uncertainty.
- MHRA: 2025/26 audited accounts — MHRA institutional funding; specific chloral warning/adviser allocations unclosed.
- eMC: publishing and payment process — Label provenance only, not neutral trial evidence.
- NHSBSA: chloral hydrate item count — England community items; not patients, indication-only use or worldwide demand.
- NHSBSA: item-count methods — Community versus hospital scope and item definition.
- NHSBSA: 2025/26 publication — Date and scope, not worldwide popularity.
- NHSBSA: 2025/26 audited institutional accounts — Institutional finance only; no drug efficacy, item accuracy or maker influence inferred.
- NHS: falls and medicine review — Falls assessment, home hazards and urgent injury care.
- 500 mg/5 ml SmPC — Safety context.
- 143 mg/5 ml SmPC — Safety context.
- 500 mg/5 ml leaflet — Safety context.
- 143 mg/5 ml leaflet — Safety context.
- Welldorm Elixir label — Safety context.
- Welldorm cloral betaine tablets: historical label — Distinct prodrug/tablet and historical age scope.
- MHRA chloral warning — Restricted use.
- RESTORE: 2026 insomnia study — Design and declared money; not proof of superiority or long-term safety.
- HRA-hosted RESTORE application — Separate sponsor identity; ethics review is not an efficacy endorsement.
- HRA: 2025/26 financial statements — Host institutional finance only.
- NHS: insomnia care — Underlying causes, CBT and routine assessment.
- NHS: poisoning emergency advice — Immediate suspected-poisoning action; no home vomiting.
- NHS: anaphylaxis — Immediate allergy action, not drug-specific incidence.
- CUH: CT under oral sedation — Supervised procedural use, separate from home insomnia.
- CUH: MRI under oral sedation — Written preparation and monitoring, not a copied sedation regimen.
- CUH: FY2025–26 audited accounts — Provider revenue only; neither chloral leaflet allocation nor sedation trial clearance.
- LactMed: chloral hydrate — Qualified breastfeeding assessment and evidence limits.
- LactMed: creation/review process — Named lead and hosting/publisher distinction.
- Anderson coauthored study: 2025 declaration — Financial-only lead audit; no chloral infant-outcome inference.
- NICHD: budget route — Publisher institutional route only.
- NICHD: gifts and partnerships — Permitted private support, not an inferred donation.
- Marlborough: legal company record — Legal holder identity, not trial evidence.
- Marlborough control — One legal control link; no outcome claim.
- Atnahs Pharma UK control — One legal control link; no outcome claim.
- Pharmanovia Bidco control — One legal control link; no outcome claim.
- Pharmanovia Midco control — One legal control link; no outcome claim.
- Pharmanovia Holdco: control statement — Explicit break in statutory control tracing.
- Pharmanovia: group identity — Group identity, separate from study results.
- Pharmanovia: FY2025 tax strategy — Documented business/debt route only.
- Triton: current Pharmanovia portfolio — Current declared backing, not clinical independence.
- Triton: legal office identities — Investor jurisdictions, distinct from UK product licence.
- Companies House: 2025/26 accounts — Register institutional route, not filing verification.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.